# Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

> **NCT00279045** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 4426 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Rosiglitazone
- **DRUG:** glyburide
- **DRUG:** metformin

## Key facts

- **NCT ID:** NCT00279045
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01-03
- **Primary completion:** 2006-06-01
- **Final completion:** 2006-06-19
- **Target enrollment:** 4426 (ACTUAL)
- **Last updated:** 2017-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00279045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00279045, "Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00279045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*